First time poster: Yesterday I did some research based on the 8/24 post stating, "Directly above in the corporate presentation it gives the following information .... Licensed to Lexington by Lawrence Berkeley National Laboratory in the field of cardiovascular vascular health diagnosis and monitoring."
While true, this is not a bad thing. The Berkeley Lab is a big science incubator, helping bring projects to fruition: http://www.lbl.gov/about.
I assume acceptance into the competitive lab is an honor, but the bottom line is that it's a quid pro quo. The Berkeley Lab provides state-of-the-art facilities as well as world-class research assistance while Lexington provides the vehicle to carry the project into the world. Not sure, but let’s assume the partnership is between the lab (university/non-profit org) and Lexington: the for-profit company. If accurate, then Lexington exists for the purpose of holding the patent rights and managing the product line. This from the website: "July 25, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the issuance of U.S. Patent No. 10,028,664, which covers aspects of its HeartSentry device."
For this partnership to work, then each side wants the other side to succeed. The Lab has done their part because Lexington received patents and is now working through the approval stages. The Lab wants Lexington to succeed or else they don't get their percentage payoff, whatever that might be. But for this arrangement to work it has to be profitable for both sides because they are now partners for at least the next 17 years of the patents.